(3-benzyl-azepan-3-yl)-(1H-indol-5-yl)-methanone | 1033815-06-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-benzyl-azepan-3-yl)-(1H-indol-5-yl)-methanone
• 英文别名: (3-benzylazepan-3-yl)-(1H-indol-5-yl)methanone
• CAS: 1033815-06-3
• 化学式: C₂₂H₂₄N₂O
• 分子量: 332.445
• InChiKey: GZMVATBMIADACI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  44.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  tert-butyl 3-benzyl-3-(1-(triisopropylsilyl)-1H-indole-5-carbonyl)azepane-1-carboxylate 在 四丁基氟化铵 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 (3-benzyl-azepan-3-yl)-(1H-indol-5-yl)-methanone
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain

  摘要：

  Two new series of monoamine triple reuptake inhibitors (TRIs) have been discovered through scaffold homologation of our recently reported series of 3,3-disubstituted pyrrolidine TRIs. The regioisomeric 2- and 3-ketopyrrolidines demonstrated high levels of potency against all three monoamine transporters as well as good human in vitro stability, low drug-drug interaction potential and a decreased propensity for hERG channel binding. Representative compounds from these series displayed good in vivo pharmacokinetics and high monoamine receptor occupancies which are indicators of good brain penetration. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.020

文献信息

• Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof
  申请人：Iyer Pravin

  公开号：US20080146607A1

  公开（公告）日：2008-06-19

  Compounds of the formula: or pharmaceutically acceptable salts thereof, wherein m, n, Ar, R 1 , R 2 , R a and R b are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

  该式化合物：或其药用可接受的盐，其中m、n、Ar、R1、R2、Ra和Rb在此处有定义。还提供了制药组合物、使用方法和制备该化合物的方法。
• HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES AND USES THEREOF
  申请人：Iyer Pravin

  公开号：US20120065225A1

  公开（公告）日：2012-03-15

  Compounds of the formula: or pharmaceutically acceptable salts thereof, wherein m, n, Ar, R 1 , R 2 , R a and R b are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

  本发明提供了公式：或其药学上可接受的盐，其中m，n，Ar，R1，R2，Ra和Rb的定义在此处。还提供了制药组合物、使用方法和制备该化合物的方法。
• Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2354124A2

  公开（公告）日：2011-08-10

  Compounds of the formula: or pharmaceutically acceptable salts thereof, wherein m, n, Ar, R1, R2, Ra and Rb are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

  式中的化合物： 或其药学上可接受的盐、 其中 m、n、Ar、R1、R2、Ra 和 Rb 在本文中定义。此外，还提供了这些化合物的药物组合物、使用方法和制备方法。
• HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2102157B1

  公开（公告）日：2011-06-22
• US8084623B2
  申请人：——

  公开号：US8084623B2

  公开（公告）日：2011-12-27